4.7 Review

Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space

期刊

LANCET INFECTIOUS DISEASES
卷 11, 期 1, 页码 57-64

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(10)70214-0

关键词

-

资金

  1. NIH [GM008719, 5-T32-AI070114-03]
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI070114] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER

向作者/读者索取更多资源

After the launch of the National Malaria Control Programme in 1953, the number of malaria cases reported in India fell to an all-time low of 0.1 million in 1965. However, the initial success could not be maintained and a resurgence of malaria began in the late 1960s. Resistance of Plasmodium falciparum to chloroquine was first reported in 1973 and increases in antimalarial resistance, along with rapid urbanisation and labour migration, complicated the challenge that India's large geographical area and population size already pose for malaria control. Although several institutions have done drug-resistance monitoring in India, a complete analysis of countrywide data across institutions does not exist. We did a systematic review of P falciparum malaria drug-efficacy studies in India to summarise drug-resistance data and describe changes over the past 30 years to inform future policy. Continued use of chloroquine for treatment of P falciparum malaria in India will likely be ineffective. Resistance to sulfa pyrimethamine should be closely monitored to protect the effectiveness of treatment with artesunate plus sulfadoxine pyrimethamine, which is the new first-fine treatment for P falciparum malaria. Strategies to reduce the emergence and spread of future drug resistance need to be proactive and supported by intensive monitoring.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据